Htr2c variants in human obesity
Eun-Seon Yoo and Jong-Woo Sohn
*
Guillaume Graciani and Tae-Young Yoon
Abstract : Targeting fibroblast growth factor receptors (FGFRs) has been slow compared to other targeted cancer therapies for receptor tyrosine kinases, such as epidermal growth factor receptors. The low efficacy and variable response have limited the growth of FGFR inhibitors in clinical use. Nevertheless, recent systematic and genomic approaches have identified the biological conditions for effectively targeting FGFRs and can accelerate the development of targeted drugs. Under clinical and preclinical trials, the inhibitors started fast growing furious races to target FGFRs. Finally, FGFRs will be more actionable and targetable with more precise and effective drugs at the end of the race, passing the finish line.
Young Hyun Jung and Ho Jae Han
Big data-based precision medicine
Daehee Hwang *
Discovery of a distinct senescent cell population in obesity-induced metabolic dysfunction
Gung Lee *
Adipocyte HIFα regulates thermogenic execution.
Ji Seul Han *
A comprehensive atlas of adipose tissue at the single-cell level
Yong Geun Jeon *
Yoonjeong Lee, Jaehyeon Kim, Hyunjin Kim, Ji Eun Han, Sohee Kim, Kyong-hwa Kang, Donghoon Kim, Jong-Min Kim, and Hyongjong Koh
Mol. Cells 2022;45: 454-464 https://doi.org/10.14348/molcells.2022.5002Narayan Bashyal, Tae-Young Lee, Da-Young Chang, Jin-Hwa Jung, Min Gyeong Kim, Rakshya Acharya, Sung-Soo Kim, Il-Hoan Oh, and Haeyoung Suh-Kim
Mol. Cells 2022;45: 479-494 https://doi.org/10.14348/molcells.2022.5015Bor Luen Tang
Mol. Cells 2016;39: 87-95 https://doi.org/10.14348/molcells.2022.5015Jin Young Huh, Yoon Jeong Park, Mira Ham, and Jae Bum Kim
Mol. Cells 2014;37: 365-371 https://doi.org/10.14348/molcells.2022.501582-2-558-0131